Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches

MAbs
Chen LiBarry L Karger

Abstract

In developing biosimilar or biobetter products, comparability to the reference product is required to claim similar integrity or intended purpose. In this work, an anti-CD20 monoclonal antibody developed using RNA interference to decrease core fucosylation (RNAi-mediated) was comprehensively characterized by LC-MS and compared with the commercially-available anti-CD20 rituximab (MabThera (®) ). As anticipated, < 30% core fucose was found within the RNAi-produced molecule (compared with > 90% in rituximab), and the reduction in fucose resulting in a significant improvement in FcγRΙΙΙa binding and antibody-dependent cell-mediated cytotoxicity. Two mutations, S258Y (fully mutated) and F174I/L (partially mutated), however, were detected in the production of the RNAi-mediated molecule. An alternative LC-MS approach using dimethyl labeling (i.e., 2CH 2 for rituximab and 2CD 2 for the RNAi-mediated molecule) was developed to additionally compare the two mAbs and confirm the full sequence with the two mutation sites. Furthermore, disulfide linkages were found to be the same for the two antibodies, with a small portion of unpaired cysteines in both products. Disulfides were correctly linked if the samples were prepared at low pH (i.e., ...Continue Reading

References

Aug 1, 1975·Canadian Journal of Biochemistry·A L Symes, T L Sourkes
Jan 1, 1982·Journal of Immunological Methods·E SchauensteinF Dachs
Jun 8, 2002·Biotechnology Progress·Wei Zhang, Marta J Czupryn
Jul 12, 2002·Analytical and Bioanalytical Chemistry·Christian K RienerHermann J Gruber
Mar 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Esther M YooSherie L Morrison
May 1, 1959·Archives of Biochemistry and Biophysics·G L ELLMAN
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinpei NiwaKenya Shitara
Oct 29, 2004·The New England Journal of Medicine·Hiroshi Okamoto, Naoyuki Kamatani
Mar 25, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinpei NiwaKenya Shitara
Mar 21, 2006·Biochemistry. Biokhimii︠a︡·N M GevondyanV S Gevondyan
Oct 7, 2006·Science·Brian T Chait
Jun 26, 2007·Nucleic Acids Research·Leonid ZamdborgNeil L Kelleher
May 14, 2008·Reviews on Recent Clinical Trials·Jose Rodriguez, Antonio Gutierrez
Mar 21, 2009·Nature Protocols·Paul J BoersemaAlbert J R Heck
Aug 20, 2009·Journal of Pharmaceutical Sciences·Stephen R BrychMasazumi Matsumura
Jan 1, 2007·Expert Review of Clinical Immunology·Peter C Taylor
Sep 12, 2012·Molecular & Cellular Proteomics : MCP·Luca FornelliYury O Tsybin

Citations

Feb 28, 2015·Expert Review of Proteomics·Jan WiesnerWolfgang Jabs
Mar 25, 2015·Journal of Mass Spectrometry : JMS·Alain BeckSarah Cianférani
May 16, 2018·Nature Communications·Beatriz TrastoyMarcelo E Guerin

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.